Silexion Therapeutics Receives Nasdaq Delisting Notice over Equity Deficiency

What Happened
Silexion Therapeutics Corp. announced on August 18, 2026 that the Nasdaq Listing Qualifications Department issued a delisting notice because the company does not meet the minimum shareholders’ equity requirement for continued listing on The Nasdaq Capital Market. The company’s Form 10-Q for the period ended June 30, 2026 (filed August 14, 2026) reported shareholders’ equity of $44,000, well below the $2,500,000 required under Nasdaq Listing Rule 5550(b)(1). Silexion intends to request an appeal before a Nasdaq Hearings Panel by the August 25, 2026 deadline.

Key Details

• Delisting notice received: August 18, 2026.
• Reported shareholders’ equity as of June 30, 2026: $44,000 (Form 10-Q filed August 14, 2026).
• Nasdaq minimum shareholders’ equity requirement (Rule 5550(b)(1)): $2,500,000.
• Appeal deadline: Company will request a hearing by August 25, 2026; prior Panel decision (Sept 23, 2025) places the company under a Mandatory Hearings Panel Monitor (Nasdaq Rule 5815(d)(4)(B)), meaning Nasdaq cannot grant additional time during the one-year monitoring period.
• If the appeal fails: trading would be suspended and a Form 25-NSE would be filed to remove the company’s ordinary shares and warrants from Nasdaq.

Why It Matters
This filing signals a material risk to Silexion’s continued Nasdaq listing and to liquidity for shareholders: the company currently falls far short of Nasdaq’s $2.5M equity standard, and a failed appeal could lead to suspension and de-listing, which typically reduces trading volume and investor access. Silexion says it will present steps to restore compliance but explicitly warns there is no assurance the appeal or any remedial actions will succeed. Investors should review the company’s recent Form 10-Q and Form 10-K risk disclosures for more detail.